Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score-Reference-Cited by-同舟云学术

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score

Published:2022-11-16 Issue:11 Volume:12 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Barbui Tiziano^ORCID,Ghirardi Arianna,Carobbio Alessandra^ORCID,Masciulli Arianna,Carioli Greta,Rambaldi Alessandro^ORCID,Finazzi Maria Chiara,Bellini Marta,Rumi Elisa,Vanni Daniele,Borsani Oscar^ORCID,Passamonti Francesco^ORCID,Mora Barbara,Brociner Marco,Guglielmelli Paola^ORCID,Paoli Chiara,Alvarez-Larran Alberto,Triguero Ana,Garrote Marta^ORCID,Pettersson Helna,Andréasson Björn,Barosi Giovanni,Vannucchi Alessandro Maria^ORCID

Funder

Novartis Pharma

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

https://www.nature.com/articles/s41408-022-00743-0.pdf

Reference8 articles.

1. Hultcrantz M, Björkholm M, Dickman PW. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population‐based cohort study. Ann Intern Med. 2018;168:317–25.

2. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115:778–82.

3. Elliott MA, Pardanani A, Lasho TL, Schwager SM, Tefferi A. Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica. 2010;95:1788–91.